---
document_datetime: 2025-12-02 06:54:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/somatropin-biopartners.html
document_name: somatropin-biopartners.html
version: success
processing_time: 0.1049901
conversion_datetime: 2025-12-24 22:01:00.227884
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Somatropin Biopartners

[RSS](/en/individual-human-medicine.xml/65918)

##### Lapsed

This medicine's authorisation has lapsed

somatropin Medicine Human Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 November 2017, the marketing authorisation of Somatropin Biopartners (somatropin) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, BioPartners GmbH, had not marketed Somatropin Biopartners in the EU since its initial marketing authorisation.

In accordance with the provisions of Article 14(4) of Regulation (EC) No 726/2004 (\"sunset clause\"), the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation. The European Commission had granted an exemption from the 'sunset clause' for Somatropin Biopartners; however the exemption expired on 8 November 2017. BioPartners GmbH confirmed that the product had not been marketed as they were unable to supply it. Somatropin Biopartners was granted marketing authorisation in the EU on 5 August 2013 for the replacement therapy of endogenous growth hormone in adults with growth hormone deficiency.

The European Public Assessment Report (EPAR) for Somatropin Biopartners is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Somatropin Biopartners : EPAR - Summary for the public

Reference Number: EMA/338086/2013

English (EN) (544.61 KB - PDF)

**First published:** 09/09/2013

**Last updated:** 01/12/2017

[View](/en/documents/overview/somatropin-biopartners-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-85)

български (BG) (632.75 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/bg/documents/overview/somatropin-biopartners-epar-summary-public_bg.pdf)

español (ES) (547.19 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/es/documents/overview/somatropin-biopartners-epar-summary-public_es.pdf)

čeština (CS) (611.68 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/cs/documents/overview/somatropin-biopartners-epar-summary-public_cs.pdf)

dansk (DA) (545.4 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/da/documents/overview/somatropin-biopartners-epar-summary-public_da.pdf)

Deutsch (DE) (549.15 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/de/documents/overview/somatropin-biopartners-epar-summary-public_de.pdf)

eesti keel (ET) (541.08 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/et/documents/overview/somatropin-biopartners-epar-summary-public_et.pdf)

ελληνικά (EL) (652.58 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/el/documents/overview/somatropin-biopartners-epar-summary-public_el.pdf)

français (FR) (549.71 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/fr/documents/overview/somatropin-biopartners-epar-summary-public_fr.pdf)

hrvatski (HR) (565.1 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/hr/documents/overview/somatropin-biopartners-epar-summary-public_hr.pdf)

italiano (IT) (1006.58 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/it/documents/overview/somatropin-biopartners-epar-summary-public_it.pdf)

latviešu valoda (LV) (692.16 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/lv/documents/overview/somatropin-biopartners-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (571.18 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/lt/documents/overview/somatropin-biopartners-epar-summary-public_lt.pdf)

magyar (HU) (605.47 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/hu/documents/overview/somatropin-biopartners-epar-summary-public_hu.pdf)

Malti (MT) (613.95 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/mt/documents/overview/somatropin-biopartners-epar-summary-public_mt.pdf)

Nederlands (NL) (542.61 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/nl/documents/overview/somatropin-biopartners-epar-summary-public_nl.pdf)

polski (PL) (609.29 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/pl/documents/overview/somatropin-biopartners-epar-summary-public_pl.pdf)

português (PT) (543 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/pt/documents/overview/somatropin-biopartners-epar-summary-public_pt.pdf)

română (RO) (571.28 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/ro/documents/overview/somatropin-biopartners-epar-summary-public_ro.pdf)

slovenčina (SK) (610.49 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/sk/documents/overview/somatropin-biopartners-epar-summary-public_sk.pdf)

slovenščina (SL) (601.17 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/sl/documents/overview/somatropin-biopartners-epar-summary-public_sl.pdf)

Suomi (FI) (542.12 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/fi/documents/overview/somatropin-biopartners-epar-summary-public_fi.pdf)

svenska (SV) (542.4 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

01/12/2017

[View](/sv/documents/overview/somatropin-biopartners-epar-summary-public_sv.pdf)

## Product information

Somatropin Biopartners : EPAR - Product Information

English (EN) (1.19 MB - PDF)

**First published:** 09/09/2013

**Last updated:** 27/04/2017

[View](/en/documents/product-information/somatropin-biopartners-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-489)

български (BG) (3.42 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/bg/documents/product-information/somatropin-biopartners-epar-product-information_bg.pdf)

español (ES) (1.43 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/es/documents/product-information/somatropin-biopartners-epar-product-information_es.pdf)

čeština (CS) (2.79 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/cs/documents/product-information/somatropin-biopartners-epar-product-information_cs.pdf)

dansk (DA) (1.35 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/da/documents/product-information/somatropin-biopartners-epar-product-information_da.pdf)

Deutsch (DE) (1.46 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/de/documents/product-information/somatropin-biopartners-epar-product-information_de.pdf)

eesti keel (ET) (1.46 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/et/documents/product-information/somatropin-biopartners-epar-product-information_et.pdf)

ελληνικά (EL) (3.53 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/el/documents/product-information/somatropin-biopartners-epar-product-information_el.pdf)

français (FR) (1.5 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/fr/documents/product-information/somatropin-biopartners-epar-product-information_fr.pdf)

hrvatski (HR) (1.36 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/hr/documents/product-information/somatropin-biopartners-epar-product-information_hr.pdf)

íslenska (IS) (1.38 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/is/documents/product-information/somatropin-biopartners-epar-product-information_is.pdf)

italiano (IT) (2.26 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/it/documents/product-information/somatropin-biopartners-epar-product-information_it.pdf)

latviešu valoda (LV) (2.75 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/lv/documents/product-information/somatropin-biopartners-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.4 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/lt/documents/product-information/somatropin-biopartners-epar-product-information_lt.pdf)

magyar (HU) (2.76 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/hu/documents/product-information/somatropin-biopartners-epar-product-information_hu.pdf)

Malti (MT) (2.71 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/mt/documents/product-information/somatropin-biopartners-epar-product-information_mt.pdf)

Nederlands (NL) (1.42 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/nl/documents/product-information/somatropin-biopartners-epar-product-information_nl.pdf)

norsk (NO) (1.44 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/no/documents/product-information/somatropin-biopartners-epar-product-information_no.pdf)

polski (PL) (2.81 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/pl/documents/product-information/somatropin-biopartners-epar-product-information_pl.pdf)

português (PT) (1.39 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/pt/documents/product-information/somatropin-biopartners-epar-product-information_pt.pdf)

română (RO) (1.43 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/ro/documents/product-information/somatropin-biopartners-epar-product-information_ro.pdf)

slovenčina (SK) (2.82 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/sk/documents/product-information/somatropin-biopartners-epar-product-information_sk.pdf)

slovenščina (SL) (2.64 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/sl/documents/product-information/somatropin-biopartners-epar-product-information_sl.pdf)

Suomi (FI) (1.39 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/fi/documents/product-information/somatropin-biopartners-epar-product-information_fi.pdf)

svenska (SV) (1.37 MB - PDF)

**First published:**

09/09/2013

**Last updated:**

27/04/2017

[View](/sv/documents/product-information/somatropin-biopartners-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0010 13/03/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Somatropin Biopartners : EPAR - All Authorised presentations

English (EN) (485.58 KB - PDF)

**First published:** 09/09/2013

**Last updated:** 09/09/2013

[View](/en/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-718)

български (BG) (522.76 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/bg/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_bg.pdf)

español (ES) (487.33 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/es/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_es.pdf)

čeština (CS) (519.22 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/cs/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (482.58 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/da/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (488.45 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/de/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (480.38 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/et/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (522.93 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/el/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_el.pdf)

français (FR) (488.47 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/fr/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (502.63 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/hr/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (481.1 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/is/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_is.pdf)

italiano (IT) (938.77 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/it/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (533.71 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/lv/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (489.01 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/lt/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (500.28 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/hu/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (519.63 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/mt/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (488 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/nl/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (488.48 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/no/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_no.pdf)

polski (PL) (533.01 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/pl/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_pl.pdf)

português (PT) (483.2 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/pt/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_pt.pdf)

română (RO) (504.85 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/ro/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (531.76 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/sk/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (509.05 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/sl/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (482.04 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/fi/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (481.05 KB - PDF)

**First published:**

09/09/2013

**Last updated:**

09/09/2013

[View](/sv/documents/all-authorised-presentations/somatropin-biopartners-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Somatropin Biopartners Active substance somatropin International non-proprietary name (INN) or common name somatropin Therapeutic area (MeSH) Growth Anatomical therapeutic chemical (ATC) code H01AC01

### Pharmacotherapeutic group

- Somatropin and somatropin agonists
- Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

Somatropin Biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (GHD).

Adult-onset: Patients with GHD in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a GHD.

Childhood-onset: In patients with childhood-onset isolated GHD (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (&lt; -2 standard-deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

## Authorisation details

EMA product number EMEA/H/C/002196 Marketing authorisation holder

BioPartners GmbH

Kaiserpassage 11

Marketing authorisation issued 05/08/2013 Lapse of marketing authorisation 09/11/2017 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Somatropin Biopartners : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (572.08 KB - PDF)

**First published:** 30/07/2014

**Last updated:** 27/04/2017

[View](/en/documents/procedural-steps-after/somatropin-biopartners-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Somatropin Biopartners : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/229458/2013

English (EN) (2.79 MB - PDF)

**First published:** 09/09/2013

**Last updated:** 09/09/2013

[View](/en/documents/assessment-report/somatropin-biopartners-epar-public-assessment-report_en.pdf)

**This page was last updated on** 01/12/2017

## Share this page

[Back to top](#main-content)